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Abstract Acute-on-chronic liver failure (ACLF) is a newly
defined clinical entity with significant morbidity and mortality
(~40–90 % at 1 year dependent on need for organ support at
presentation). It defines a presentation with acute severe liver
injury, often with multiorgan dysfunction, on a background of
previously known or unknown cirrhosis. In its severest form, it is
almost indistinguishable from acute liver failure, as similarly in
around 5%may rapidly progress to intracranial hypertension and
cerebral oedema culminating in coma and/or death. Our under-
standing of such cerebral sequelae is currently limited to clinical
observation, though our knowledge base is rapidly expanding
since recent consensus clinical definition and guidance. More-
over, there are now animal models of ACLF and imaging
modalities to better characterize events in the brain that occur
with ACLF. However, as yet there has been little in the way of
interventional study of this condition which are much needed. In
this review we dissect existing clinical and experimental data to
better characterise the manifestations of ACLF on the brain and
allow for the development of targeted therapy as currently the
plethora of existing interventions were designed to treat either the
effects of cirrhosis or acute liver injury independently.
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Introduction
Acute-on-chronic liver failure (ACLF) is a new clinical entity
with significant morbidity and mortality. In its severest form it
is almost indistinguishable from acute liver failure, aside from
background cirrhosis, as similarly may rapidly progress to
intracranial hypertension and cerebral oedema culminating in
coma and/or death. This happens in around 5 %, but our
understanding of such cerebral sequelae is limited as little
clinical or animal model data exists to-date. In this review we
dissect existing clinical and experimental data to better charac-
terise themanifestations of ACLF on the brain and allow for the
development of targeted therapy as currently the plethora of
existing interventions were designed to treat either the effects of
cirrhosis or acute liver injury independently.
Types of liver failure
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome
that may develop with advancing liver insufficiency and helps
define the differing clinical syndromes of liver failure. Acute
liver failure (ALF) is defined by the presence of HE within 8-
weeks of the initial liver insult, in the absence of chronic liver
disease (e.g. cirrhosis). In its most advanced stages it is associ-
ated with intracranial hypertension and possible death from
brain herniation (Clemmesen et al. 1999). In cirrhosis, HE
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typically occurs insidiously with wide ranging neuropsychiatric
disturbances (e.g. psychomotor dysfunction, impaired memory,
decreased reaction time, diminished attention, sensory abnor-
malities and poor concentration). However, there is a growing
number of patients with cirrhosis presenting more acutely in a
manner better represented by ALF, with acute end-organ dys-
function(s) requiring support. This new clinical entity - termed
‘acute-on-chronic liver failure’ (ACLF), defines acute deterio-
ration in patients with cirrhosis that triggers cerebral and clin-
ical changes indistinct from ALF.
One of the first attempts to define ‘acute-on-chronic liver
failure’ (ACLF) was by the London group in 2002 who
suggested that ACLF encompasses the development of cere-
bral and clinical changes indistinct from ALF following acute
liver injury on the background of chronic liver disease (Sen
et al. 2002). However, as a new clinical entity, consensus over
what defines ACLF remains both topical and debated. The
most accepted ACLF definition to date have been set out by:
1) the Asia-Pacific Association for the Study of Liver Dis-
ease (APASL)—‘Acute hepatic insult manifesting as
jaundice and coagulopathy, complicated within 4 weeks
by ascites and/or encephalopathy in a patient with previ-
ously diagnosed or undiagnosed chronic liver disease’
(Sarin et al. 2009).
2) EASL-AASLD single topic symposium—‘Acute deteri-
oration of pre-existing chronic liver disease, usually re-
lated to a precipitating event and associated with in-
creased mortality at 3 months due to multi-system organ
failure’ (Olson et al. 2011).
ACLF is distinct
On review of existing ACLF data, there is marked variance in
hard clinical outcomes such as ICU mortality (35 to 89 %) and
in-hospital mortality (43 to 88 %). This disparity may directly
reflect the definition used and the resultant therapeutic and
management practices applied. Given differing morbidity and
mortality outcomes there is a fundamental need to provide a clear
distinction between ‘true’ACLF and less severe decompensated
chronic liver disease. In ACLF patients requiring intensive care
unit (ICU) support (Olson et al. 2011), reported 53 % ICU
mortality (and mean 14-day hospitalization), whereas others
suggest a mortality as high as 89 % (Levesque et al. 2013).
Higher mortality is usually indicated by the extent of organ
support required at admission, with Levesque et al. reporting
89 % 1-year mortality in those requiring mechanical ventilation.
In support of earlier ACLF literature, prognostic severity scores,
need for other organ support therapy, infection and total bilirubin
at ICU admission were associated with high rates of ICU mor-
tality. They also report that of the 34 % discharged from ICU, 1-
year survival was still only 32 %; with total bilirubin <64.5
micromol/L and length of ventilation >9 days were independent
indicators of poor prognosis (Levesque et al. 2013).
Given increasing shortage of ICU capacity, such mortality
risk stratifiers could temper our enthusiasm to provide early
support for ACLF patients if certain indicators are
unfavourable at presentation. However, morbidity and mortal-
ity has improved significantly for this at risk group due to early
organ support and/or restorative intervention and that targeting
the earlier identification of this at-risk group at hospital admis-
sion with early high-intensity care may be more beneficial in
terms of morbidity, mortality and health-economic consider-
ations. As such development of ACLF care-bundles (covering
the first 48–72-hours of admission) to aid access and applica-
tion of best-practice and specialist care is warranted.
The brain in ACLF
Clinical description of the brain in ACLF
As with ALF, HE is a common manifestation of ACLF (Jalan
et al. 2002) and from the pathophysiological perspective sim-
ilarly may progress to intracranial hypertension and cerebral
oedema (Crippin et al. 1992; Jalan et al. 1997; Donovan et al.
1998). In respect to the changes within the brain in ACLF, the
first acknowledgement of this hitherto unknown phenotype as
distinct from decompensated cirrhosis and ALF was reported
by Jalan et al. 1997; (Jalan et al. 1997) They described the
previously unreported phenomenon of acute intracranial hy-
pertension and oedema (c.f. ALF) in four patients with cirrho-
sis following emergency transjugular intrahepatic porto-
systemic shunt (TIPS) for variceal haemorrhage, associated
with a marked deterioration in liver function tests. The current
explanation for this post-TIPS effect relates to increased sys-
temic microbial load secondary to redirected portal blood into
the systemic circulation with therapeutic shunting. Such
changes are associated with increased nitric oxide (NO) pro-
duction possibly through an iNOS dependent mechanismwith
severe pathophysiological effects leading to circulatory failure
in the critically ill cirrhotic patient (Jalan et al. 2011).
Donovan et al. later described their experience of 12 pa-
tients presenting with acutely decompensated cirrhosis with
clinical and radiological evidence of raised ICP and brain
oedema. They successfully treated two patients with trans-
plantation which resulted in clinical neurological resolution.
This importantly shows a reversible component to the ACLF
brain, further indicating a potential therapeutic window for
intervention to target cerebral sequelae of clinical ACLF and
hopefully improve morbidity and mortality in this hitherto
often fatal clinical presentation (Donovan et al. 1998).
Cordoba et al. expanded on our clinical understanding of
the cerebral effects of ACLF by showing in similarly
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cerebrally obtunded ACLF patients demonstrating resolution
of cerebral oedema and amelioration of cerebral
haemodynamics on MRI, again highlighting the potential for
reversibility, similar to that seen with ALF, despite the back-
ground cirrhotic brain phenotype (García Martínez et al.
2010). Moreover, in a recent large comparative clinical study
of consecutive decompensated cirrhosis (n=138) versus
ACLF (n=301) patients, from the CANONIC Study database,
Cordoba et al. elegantly demonstrate that HE associated with
ACLF predominately occurs in younger often alcoholic pa-
tients, associated with more severe liver failure and systemic
inflammatory response syndrome (SIRS) with extremely poor
prognosis with age, bilirubin, INR, creatinine, sodium and HE
grade, independent risk factors for mortality. Conversely de-
compensated disease occurred more frequently in older usu-
ally inactive drinkers, without severe liver failure or SIRS and
often associated with diuretic use (Cordoba et al. 2014).
There has often been debate as to how frequently brain
oedema and raised ICP in ACLF occurs, but new data from
Joshi et.al., indicates that less than 1 in 20 (~5 %) of such
ACLF patients formally progress to such an advanced stage
(Joshi et al. 2013). This is likely to be an underestimation as
the patients were not monitored and given that patients with
cirrhosis have some degree of cerebral atrophy, any cerebral
oedema will not result in obvious clinical manifestations of
increased intracranial pressure.
Other local and systemic factors have been implicated in
the pathophysiology and development of this neurological
syndrome. Changes in ammonia levels and inflammatory
status, along with changes in cerebral haemodynamics make
up our current paradigm for HE pathogenesis but their relative
contribution to progression of HE in ACLF as opposed to that
seen with ALF and cirrhosis has not been clearly defined
(Shawcross et al. 2011). The importance of infection/SIRS
in precipitating HE is well described in ALF and cirrhosis, but
not so in ACLF. Shawcross et.al, have recently demonstrated
the somewhat expected correlation between infection/SIRS
and advanced HE (grades 3–4) in cirrhotic patients admitted
to ITU primarily for encephalopathy (Shawcross et al. 2011).
This study also discusses the relative role of ammonia in
development of HE in ACLF, as plasma ammonia was not
clearly associated with advancing HE but most patients were
hyperammonaemic.
Evidence of brain oedema in ACLF
As there is no human histopathological support for the clinical
findings in ACLF, there is a reliance on interpretation of
animal data in models of ACLF along with the translation of
clinical data from ALF and cirrhosis patients where similari-
ties exist. Precipitants of advanced HE in ACLF are the same
triggers for general decompensated cirrhosis and it remains
unclear as to why in any one patient a neurological decline to
intracranial hypertension and cerebral oedema ensues. One
can postulate that a shift in neurophysiology may be triggered
by either 1) a more significant pathological challenge (e.g.
microbial inoculate dose, massive GI bleed and/or SIRS etc.),
2) background liver capacity and/or 3) local brain neurophys-
iology and anatomy. This latter point has been suggested in
data from rat models of ACLF around a concept of ‘priming’,
which will be discussed later.
Pathogenic synergism ammonia and inflammation Ammonia
has been shown to correlate with the severity of HE in cir-
rhotic patients (Ong et al. 2003), and predict brain herniation
in patients with ALF (Clemmesen et al . 1999) .
Pathophysiologically, astrocyte metabolism of ammonia pro-
duces accumulation of osmotically active glutamine to pro-
duce brain oedema and intracranial hypertension (Haussinger
et al. 1994; Cordoba et al. 1996; Tofteng et al. 2006). In
patients with ALF, SIRS (often secondary to infection) corre-
lates with advancing stages of HE and intracranial hyperten-
sion (Rolando et al. 2000; Vaquero et al. 2003). We have
previously reported a correlation between intracranial hyper-
tension and both circulating and brain levels of pro-
inflammatory cytokines in ALF patients (Jalan et al. 2004;
Wright et al. 2007a). In patients with cirrhosis and
SIRS/infection, induced hyperammonaemia worsened neuro-
psychological function; this suggests pathogenic synergy be-
tween hyperammonaemia and inflammation (Shawcross et al.
2004). However, from these clinical studies it is not clear
whether it is the background state of the brain in cirrhosis or
the associated hyperammonaemia that predisposes to the ef-
fects of the superimposed inflammation. In a histological
study of a rodent model of ACLF, Wright et al., observed that
acute severe microbial (Lipopolysaccharide; LPS) challenge
to bile-duct ligated (BDL) rat model of cirrhosis induced
marked increase in brain water (with astrocyte and associated
perivascular oedema), mimicking ACLF. However, more se-
vere LPS-induced brain oedema was evident in naïve non-
cirrhotic rats with induced hyperammonaemia. Interestingly,
only LPS challenged BDL rats reached pre-coma stages at 3-
hours despite more severe brain oedema in LPS-challenged
hyperammonaemic naïve rats. This decoupling of increased
brain water and preserved mental state in all rats except LPS-
treated cirrhotic rats suggests that factors in addition to in-
flammation, hyperammonaemia and resultant brain swelling
contribute to the effects on consciousness found in HE.
Blood brain barrier integrity (Cytotoxic versus Vasogenic
Oedema) Histological analysis indicates that increases in brain
water are indistinguishable from the well-documented brain
oedema seen in hyperammonaemic ALF models. However,
distinct from these ALF models where the blood–brain barrier
(BBB) was observed to be compromised (Traber et al. 1986;
Kato et al. 1989) the anatomical integrity of the BBB is
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maintained with retention of the ionic tracer lanthanum nitrate
(Molecular weight 433 kDa) on electron microscopy. This
difference may suggest a specific phenomenon of cytotoxic
oedema in cirrhotic rats compared with a combined cytotoxic
and vasogenic oedema in ALF. Wright et al., also looked at
possible associated pathophysiological changes in the brain
physiology. The astrocytic oedema in the non-cirrhotic
hyperammonaemic rats was expectedly associated with in-
creased glutamine, reduction in myo-inositol and a marked
increase in the glutamine/myo-inositol ratio in keeping with
the ammonia-glutamine-brain water hypothesis. However,
the mild astrocytic oedema seen in the saline-treated BDL
rats was markedly less despite similar degrees of plasma and
brain ammonia levels as seen with the LPS-administered
BDL group. The mechanisms underpinning astrocytic
swelling in cirrhotic rats are therefore unclear and possibly
influenced by the effects of inflammation. Yet worsening
oedema following LPS-challenge in this study did not di-
rectly correlate with plasma and brain ammonia levels or
brain ammonia metabolism. These experimental data may
provide some insight into why ammonia levels show no
direct correlation with advanced HE (grade 4) and outcomes
in the clinical ACLF study by Joshi et.al., reported earlier
(Joshi et al. 2013).
Systemic versus brain inflammatory processes Uniquely this
study also tied the marked SIRS (peripheral trigger) to brain
inflammatory responses with increased brain tissue TNF-α
confirming our previous observation that a systemic inflam-
matory response may initiate brain inflammation during liver
failure despite retained anatomical barrier integrity. In BDL
rats high nitric oxide levels and hyperammonaemia were
further associated with ammonia-induced nitrosation of astro-
cytic proteins (e.g. protein tyrosine nitration -PTN). Although
inflammation may act synergistically with ammonia, LPS can
itself lead to nitrosation of proteins in the brain (Lee et al.
2005). This may indicate that in cirrhosis, the existent back-
ground hyperammonaemia and low-grade inflammatory cere-
bral milieu (Jover et al. 2006) may ‘prime’ the animal to the
effect of subsequent endotoxaemic/inflammatory insult. This
concept of pathogenic synergy fits with the clinical data
(Shawcross et al. 2004).
Role of oxidative stress Whether due to local cellular (e.g.
astroglial) dysfunction, or peripherally (e.g. other end-
organ dysfunction and/or circulating cells like neutro-
phils), resultant free-radical formation and/or oxidative
stress, the cellular dysfunction caused by imbalanced
creation, breakdown or inhibition of reactive oxygen
species (ROS) and/or antioxidants, appear equally piv-
otal to ammonia-induced neurotoxicity. Data from both
animal and human studies also suggest potential patho-
genic synergy between systemic oxidative stress, and
ammonia in HE, with rising ammonia levels associated
with progressive oxidative stress and also free-radical
production mediated by NMDA-receptor activation and
ammonia-induced mitochondrial dysfunction (Marcaida
et al. 1992). This could also be a source of ROS such
as peroxynitrite (OONO•), itself mediating NO-induced
blood brain barrier damage and astocyte dysfunction
(potentially through PTN), which has been shown in
models of hyperammonaemic acute or chronic liver
injury and in cell culture (Bosoi et al. 2012;
Jayakumar et al. 2006; Norenberg et al. 2005; Schliess
et al. 2004; Rao et al. 2001); we have similarly shown
this in a LPS-challenged BDL model of ACLF (Wright
et al. 2007b). Oxidative stress occurs more robustly
with the acute and significant hyperammonaemic insult
of ALF and ACLF (Wright et al. 2007a, b), as opposed
to the more insidious, though no less profound
hyperammonaemia of CLD. This is an interesting obser-
vation which again points to the importance of the
chronicity of injury rather than absolute level of
hyperammonaemia in the clinical phenotype of HE.
The likely importance of oxidative stress in HE patho-
genesis also provides a the rationale for using antioxi-
dants (e.g. N-Acetylcysteine) to ameliorate brain sequel-
ae associated with advanced liver disease, which has
proven beneficial in animal models of HE (Guerrini
1994).
Role of cerebral haemodynamics Cerebral blood flow
(CBF) is integral to the HE pathogenesis and likely
directly linked to alterations in both ammonia and in-
flammation as they independently influence cerebral
haemodynamics (discussed later). As already discussed,
they appear to act synergistically, which has even been
shown to influence CBF in non-cirrhotic rat models
(Pedersen et al. 2007). Development of cirrhosis is
known to engender a progressively reduced CBF (cere-
bral oligaemia); in contrast ALF is associated to large
increases in CBF (cerebral hyperaemia) and eventually
ICP, brain oedema, coma and/or death from brain her-
niation. Paradoxically CBF may increase significantly in
ACLF to mimic ALF. In a seminal study of cirrhotic
patients receiving TIPS for either GI bleeding or ascites,
TIPS-induced endotoxaemia led to an increase in the
rate of production of nitric oxide, which was associated
with endothelial dysfunction and an increase in CBF
(Jalan et al. 2011). However, insertion of TIPS in rela-
tively stable cirrhotics in the absence of HE had no
effect on CBF, indicating the likely pathophysiologically
distinct nature of ACLF (Iversen et al. 2011). These
observation also support the hypothesis that multiple
hits and brain swelling is central to the brain manifes-
tations of ACLF.
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Role of imaging techniques Given the distinct lack of histo-
logical evidence from patients with ACLF, neuroimaging
modalities allow for non-invasive assessment of brain alter-
ations in liver failure to better establish the pathogenic mech-
anisms involved. As the sensitivity ofMRImachines improve,
it is likely in the not so distant future, this technique will
provide a better understanding of HE mechanisms that may
prove useful for early diagnosis, local therapy design and
monitoring of cerebral complications of liver failure
(Chavarria and Cordoba 2013). Nath et al., in a smaller
imaging study (using diffusion tensor imaging (DTI) metrics)
of 23 ACLF patients compared to healthy controls, demon-
strated both intracellular and extracellular brain oedema (Nath
et al. 2008). The same group further compared changes in
brain osmolytes with ALF, ACLF and stable cirrhosis versus
healthy controls (n=10/group) using in vivo1H magnetic res-
onance spectroscopy (Verma et al. 2008) demonstrating lower
osmotically active myo-inositol and glutamate/glutamine
levels within the brain of ACLF patients. If the astrocyte brain
water-glutamine hypothesis is true, this may suggest that the
extent of brain oedema in ACLF is less profound than evident
with ALF, a concept consistent with the change from
vasogenic to cytotoxic with advanced HE grade (e.g. 3–4) in
ALF. Recently however, brain lactate, both a brain osmolyte
and one of the most important brain energy sources, has been
implicated in progression of HE and cerebral oedema in rat
models, with rising levels associated with advance stages and
a potential therapeutic target (Bosoi et al. 2013). A rise in
cerebral lactate may occur due to 1) hyperlactataemia related
to compromised end-organ circulation which then crosses the
BBB, 2) increased glycolysis due to energy failure or impair-
ment and/or (3) increased lactate production/release or de-
creased lactate utilization/uptake (Rose 2010). Regardless,
aiming to reduce brain lactate by inhibiting lactate synthesis
is not without concern as lactate cannot be replaced by glucose
as an energy source. Any resultant lack of energy sources
could lead to a worsening of the functionality of the brain,
inducing worsening of the motor and memory deficits (Oria
and Jalan 2013). It therefore remains likely that the increase in
brain lactate is a consequence of pathophysiological mecha-
nisms rather than its cause.
Animal models of ACLF
To-date there are limited animal models of ACLF. This is not
unsurprising given that the clinical syndrome has only recent-
ly been established and still under a dynamic process of
characterization. However, what is common to all reported
models of ACLF is the need to initially induce chronic hepatic
fibrosis/cirrhosis before induction of failure with developing
pathophysiological changes reflecting the typical clinical se-
quelae. As expressed there has been little advances in recent
years to suggest the establishment of newer models of ACLF
(Belanger and Butterworth 2005). The most validated ACLF
models are:
D-Galactosamine/LPS-induced inflammatory liver injury
model: This ACLF model was first characterised by Liu and
colleagues (Liu et al. 2007) and since utilized in a number of
notable studies (Kuhla et al. 2009; Wang et al. 2012). It involves
the induction of immune liver fibrosis in rats by multi-point
0.5 ml subcutaneous injections of human serum albumin
(HSA), diluted to a concentration of 8 g/L with physiological
saline (emulsified by an equal amount of incomplete Freund’s
adjuvant). There is a 14-day interval between the first and second
injection and 10-day interval between third and fourth. Then, a
further 4 mg HSAwas injected into rat tail vein twice a week for
6 weeks. Following induced immune liver fibrosis the rats are
injected with intraperitoneal D-galactosamine (400 mg/kg) com-
bined with LPS (100 μg/kg) to induce secondary ALF on a
background of chronic liver injury.
BDL/LPS-induced ACLF model This model has been used for
some time (Harry et al. 1999) and more formally characterized
as a model of ACLF by Wright and colleagues (Wright et al.
2007a, b) with special attention to the brain sequelae of this this
condition. It involves the induction of secondary biliary fibrosis/
cirrhosis by operative BDL, performed on rats under anaesthesia
(intravenous diazepam (1 mg/kg), followed by intramuscular
Hypnorm® (150 μl/kg)). It involves midline laporotomy and
identification of the bile duct with ‘triple’ ligation and then
isolation and severance of the bile duct. After post-operative
recovery the BDL rats are kept under regulated and controlled
conditions with free access to food and water and development
of secondary biliary cirrhosis over the following 4–6weeks with
clear evidence of decompensation (e.g. jaundice, ascites). Prior
to termination the BDL rats are administered LPS (1 mg/kg) to
induce superimposed acute liver injury/failure.
Multicellular interactions, synergy, priming and immune
adaptation
Given the involvement of both systemic and regional end-
organ responses, inflammation, ammonia (and amino-acid
metabolism) and cerebral haemodynamics, it is important to
consider how cellular interactions within the brain allow for
these pathophysiological observations.
Ammonia is likely to act as the priming stimulus on the
background of which inflammation may produce HE. This
concept is supported by interventional studies, a good exam-
ple of this is the lowering of circulating ammonia with the
novel therapy ornithine phenylacetate (OP), which protected
against the brain swelling associated with liver failure (Davies
et al. 2009), Ammonia is detoxified by the astrocytes in the
brain and swell during hyperammonaemia due to the osmotic
effect of glutamine (Haussinger et al. 2000). Astrocytes form
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an integral component of the blood–brain barrier and regulate
cerebral blood flow through an arachidonic acid dependent
pathway (Takano et al. 2006). This observation directly links a
possible mechanism that may underlie the synergy between
ammonia and inflammation in which astrocytes are the critical
cells. Hyperammonaemia may therefore activate astrocytes
‘unlocking’ the blood–brain barrier (Jalan et al. 2007), making
them susceptible to endotoxaemia through a Cyclo-
oxygensase (COX)-dependent mechanism. There is also
newer evidence proposing a role for microglia (Wright et al.
2013) and pericytes in the regulation of cerebral
haemodynamics via their recently reported regulatory role
on capillary vascular tone (Peppiatt et al. 2006) but their role
in ACLF is still unclear.
Approaches to prevention and treatment
Ammonia, inflammation, modulation of CBF autoregulation
and the precipitants of acute liver injury are central to the
cerebral sequelae of ACLF and therefore, important therapeu-
tic targets in the management paradigm. Despite numerous
therapeutic approaches to the wide spectrum of neuropsychi-
atric presentations with liver failure, there is a need for more
interventional therapies for those patients with ACLF, as with
ALF. Therapies are therefore focused on this mechanisms
underpinning this pathogenic mechanisms outlined above.
Modulation of ammoniagenesis and inflammatory processes,
without compromising global brain homeostasis or inducing
systemic complications, therefore remains the key to defining
new therapeutic strategies for HE.
In ACLF that progresses to cerebral oedema with intracra-
nial hypertension and resultant coma, the need to treat the
multi-organ effects of liver failure are inseparable from
treating its cerebral effects. Early ventilation, intensive care
unit admission and judicious use of available therapies have
led to a significant decline in deaths as a result of cerebral
sequelae. Treating precipitating factors is as crucial as directly
aiding liver recovery by prompt and specific treatment of the
cause of acute liver injury. Though ACLFmay be triggered by
such uncommon events as sedatives or tranquilizers, vascular
occlusion (hepatic vein or portal vein thrombosis) and hepa-
tocellular carcinoma transformation, it is paramount to man-
age the more common precipitants such as constipation, elec-
trolyte and acid–base imbalance, infection, gastrointestinal
bleeding and portosystemic shunts. However, general man-
agement of true ACLF requires a multi-organ approach, espe-
cially for those in need of formal organ support, given the high
mortality rates. There have been no formal clinical ACLF
studies directly assessing therapies targeting cerebral effects
but what is understood is the applied benefit of ALF therapies,
which principally influence cerebral haemodynamics to limit
ICP and brain oedema. Figure 1 summarises some of the
strategies that need to be assessed in ACLF patients.
General
Ventilation Early airway maintenance and intubation prevents
high carbon dioxide tension and hypoxia limiting cerebral
hyperaemia (Ede et al. 1986). Good airways protection limits
risk of aspiration, defective gas exchange and infection.
Propofol is often preferred as the sedative because it reduces
ICP (though may cause hypotension) (Wijdicks and Nyberg
2002), and due to non-hepatic metabolism does not accumulate.
Circulatory support and fluid management Like ALF, ACLF
is a hyperdynamic state with high cardiac output, low mean
arterial pressure (MAP), and low systemic vascular resistance.
Moreover given background cirrhosis there is already gener-
alized vasodilatation, profound neurohormonal activation and
resultant vasoconstricted regional vascular beds (Jalan 2005).
MAP should be maintained at a level to keep CPP between 50
and 65 mmHg (Davies et al. 1994). Ensuing Multi-organ
failure (MOF) often necessitates inotropes; in those refractory
to inotropes a short synacthen test on ITU admission guides
steroid use as adrenal insufficiency (common in cirrhosis)
(Harry et al. 2002).
Electrolyte imbalance Hyponatraemia ≤125 mmol/Lmay pre-
cipitate cerebral oedema and is a contraindication for
orthotopic liver transplant (OLT) (Jalan et al. 1997; Cordoba
et al. 1998). In ALF, induced hypernatraemia may improve
ICP and reduce inotropic requirements (Murphy et al. 2004),
though potential benefit has not been formally assessed in
ACLF patients.
Antibiotic/antimicrobial agent Given the incidence of
infection/SIRS related neurological decline, empirical broad-
spectrum antibiotics/antifungal is a requirement and should be
targeted once an organism identified (Rolando et al. 1990, 2000).
Glycaemic control Disturbed glycaemic and lipid control is
common in progressive liver disease and worsened by the
stress response in ACLF that could provoke neuroglycopenia
and brain oedema. Tight glycaemic control using insulin
reduces oxidative stress (which triggers insulin resistance),
limits mitochondrial liver damage, and improves endothelial
nitric oxide activation to optimize blood flow, limiting tissue
injury, and improve outcomes (Langouche et al. 2005; Houstis
et al. 2006).
Specific
In ALF there are many therapies utilized to lower intracranial
hypertension and oedema. However such therapies (e.g.
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mannitol, hypothermia, hypernatraemia, anti-epileptics and
indomethacin) currently have no evidence in ACLF and re-
quire evaluation in specific ACLF clinical trials. In respect to
ammonia-lowering therapy, although disaccharides are useful
in ALF, the data of its usefulness in ACLF patients is lacking.
Otherwise none of the ammonia-lowering therapies have been
trialled in this condition although as discussed previously
ornithine phenylacetate may have a role but will need to be
proven in appropriate clinical trials.
Albumin dialysis using molecular adsorbents recirculating
system The extracorporeal device that has had the most clinical
evaluation is the ‘Molecular Adsorbent Recirculating System
(MARS)’ that provides counter-current dialysis against albumin
and bicarbonate circuits. Albumin dialysiswithMARSdecreases
retained substances and improves haemodynamics and HE. In a
randomised clinical trial of MARS in ACLF patients performed
in the US, there was a significant benefit of MARS in reducing
the time to wake up and effectiveness. In another multinational,
multicentre trial of 189 ACLF patients randomized to MARS
(n=95) or standard therapy (SMT) (n=94), there was no signif-
icant beneficial effect of MARS on 28-day survival (~60 %).
However, MARS had an acceptable safety profile, significant
dialysis effect and non-significantly improved advanced HE (3–
4) grades (Bañares et al. 2013).
Conclusion
The brain sequelae of clinical ACLF are often profound and
associated with significant morbidity and mortality. As yet there
has been little study in either humans or animalmodels of ACLF
that allow us to better elucidate the histopathophysiological
characteristics and define the syndrome. However, there is some
understanding of managing the clinical presentation using a
plethora of interventions targeting the pathogenic paradigm of
ammonia, inflammation and cerebral haemodynamic dysregu-
lation which are central to the pathogenesis of HE. A greater
understanding of the interplay between interorgan ammonia and
amino acid metabolism, inflammatory responses and cerebral
haemodynamic in ACLF is likely to lead to the development of
new therapeutic approaches.
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reproduction in any medium, provided the original author(s) and the
source are credited.
References
Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Saliba
F, Sauerbruch T, Klammt S, Ockenga J, Pares A, Wendon J,
Brünnler T, Kramer L, Mathurin P, de la Mata M, Gasbarrini A,
Müllhaupt B, Wilmer A, Laleman W, Eefsen M, Sen S, Zipprich A,
Tenorio T, Pavesi M, Schmidt HH,Mitzner S,Williams R, ArroyoV
(2013) RELIEF study group. Extracorporeal albumin dialysis with
the molecular adsorbent recirculating system in acute-on-chronic
liver failure: the RELIEF trial. Hepatology 57(3):1153–1162
Belanger M, Butterworth RF (2005) Acute liver failure: a critical apprais-
al of available animal models. Metab Brain Dis 20:409–423
Bosoi CR, Yang X, Huynh J, Parent-Robitaille C, Jiang W, Tremblay M,
Rose CF (2012) Systemic oxidative stress is implicated in the
pathogenesis of brain edema in rats with chronic liver failure. Free
Radic Biol Med 52:1228–1235
Fig. 1 Target Therapies for brain
effects of ACLF
Metab Brain Dis (2014) 29:965–973 971
Bosoi CR, ZwingmannC,MarinH, Parent-Robitaille C, Huynh J et al (2013)
Increased brain lactate is central to the development of brain edema in
rats with chronicliverdisease. J Hepatol. doi:10.1016/j.jhep.2013.10.011
Chavarria L, Cordoba J (2013)Magnetic resonance of the brain in chronic
and acute liver failure. Metab Brain Dis. doi:10.1007/s11011-013-
9452-9
Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P (1999)
Cerebral herniation in patients with acute liver failure is correlated
with arterial ammonia concentration. Hepatology 29:648–653
Cordoba J, Gottstein J, Blei AT (1996) Glutamine, myo-inositol, and organic
brain osmolytes after portocaval anastomosis in the rat: implications for
ammonia-induced brain oedema. Hepatology 24:919–923
Cordoba J, Gottstein J, Blei AT (1998) Chronichyponatremia exacerbates
ammonia-induced brain edema in rats after portacaval anastomosis.
J Hepatol 29:589–594
Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós A, Pavesi M,
Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo
V (2014) CANONIC Study Investigators of the EASL-CLIF
Consortium. Characteristics, risk factors, and mortality of cirrhotic
patients hospitalized for hepatic encephalopathy with and without
acute-on-chronic liver failure (ACLF). J Hepatol 60:275–281
Crippin JS,Gross JB Jr, LindorKD (1992) Increased intracranial pressure and
hepatic encephalopathy in chronic liver disease. Am J Gastroenterol 87:
879–882
Davies MH, Mutimer D, Lowes J, Elias E, Neuberger J (1994) Recovery
despite impaired cerebral perfusion in fulminant hepatic failure.
Lancet 343:1329–1330
Davies NA, Wright G, Ytrebo LM, Stadlbauer V, Fuskevag OM,
Zwingmann C, Davies DC et al (2009) L-ornithine and
phenylacetate synergistically produce sustained reduction in ammo-
nia and brain water in cirrhotic rats. Hepatology 50:155–164
Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF (1998) Cerebral edema
and increased intracranial pressure in chronic liver disease. Lancet 351:
719–721
Ede RJ, Gimson AE, Bihari D, Williams R (1986) Controlled hyperven-
tilation in the prevention of cerebral oedema in fulminant hepatic
failure. J Hepatol 2:43–51
García Martínez R, Rovira A, Alonso J, Aymerich FX, Huerga E, Jacas C
et al (2010) A long-term study of changes in the volume of brain
ventricles and white matter lesions after successful liver transplan-
tation. Transplantation 89:589–594
Guerrini VH (1994) Effect of antioxidants on ammonia induced CNS-
renal pathobiology in sheep. Free Radic Res 21:35–43
Harry D, Anand R, Holt S, Davies S, Marley R, Fernando B, Goodier D
et al (1999) Increased sensitivity to endotoxemia in the bile duct-
ligated cirrhotic rat. Hepatology 30:1198–1205
Harry R, Auzinger G, Wendon J (2002) The clinical importance of adrenal
insufficiency in acute hepatic dysfunction. Hepatology 36:395–402
Haussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M,
Gerok W et al (1994) Proton magnetic resonance spectroscopy
studies on human brain myo-inositol in hypo-osmolarity and hepatic
encephalopathy. Gastroenterology 107:1475–1480
Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S (2000)
Hepatic encephalopathy in chronic liver disease: a clinical manifes-
tation of astrocyte swelling and low-grade cerebral edema? J
Hepatol 32:1035–1038
Houstis N, Rosen ED, Lander ES (2006) Reactive oxygen species have a
causal role in multiple forms of insulin resistance. Nature 440:944–
948
Iversen P, Keiding S, Mouridsen K, Ott P, Vilstrup H (2011) Transjugular
intrahepatic portosystemic shunt does not alter cerebral blood flow.
Clin Gastroenterol Hepatol 9:1001–1003
Jalan R (2005) Acute liver failure: current management and future pros-
pects. J Hepatol 42(Suppl):S115–S123
Jalan R, Dabos K, Redhead DN, Lee A, Hayes PC (1997) Elevation of
intracranial pressure following transjugular intrahepatic
portosystemic stent-shunt for variceal haemorrhage. J Hepatol 27:
928–933
Jalan R, Pollok A, Shah SH, Madhavan K, Simpson KJ (2002) Liver
derived pro-inflammatory cytokines may be important in producing
intracranial hypertension in acute liver failure. J Hepatol 37:536–
538
Jalan R, OldeDamink SW, Hayes PC, Deutz NE, Lee A (2004)
Pathogenesis of intracranial hypertension in acute liver failure:
inflammation, ammonia and cerebral blood flow. J Hepatol 41:
613–620
Jalan RG, Davies NA, Hodges SJ (2007) L-Ornithine Phenylacetate
(OP): a novel treatment for hyperammonemia and hepatic enceph-
alopathy. Med Hypotheses
Jalan R, OldeDamink SW, TerSteege JC, Redhead DN, Lee A, Hayes PC
et al (2011) Acute endotoxemia following transjugular intrahepatic
stent-shunt insertion is associated with systemic and cerebral vaso-
dilatation with increased whole body nitric oxide production in
critically ill cirrhotic patients. J Hepatol 54:265–271
Jayakumar AR, Panickar KS, Murthy Ch R, Norenberg MD (2006)
Oxidative stress and mitogen-activated protein kinase phosphoryla-
tion mediate ammonia-induced cell swelling and glutamate uptake
inhibition in cultured astrocytes. J Neurosci 26:4774–4784
Joshi D, O’Grady J, Patel A, Shawcross D, Connor S, Deasy N, Willars
C, Bernal W, Wendon J, Auzinger G (2013) Cerebral oedema is rare
in acute-on-chronic liver failure patients presenting with high-grade
hepatic encephalopathy. Liver Int. doi:10.1111/liv.12257 [Epub
ahead of print] PMID: 23844567]
Jover R, Rodrigo R, Felipo V, Insausti R, Saez-Valero J, Garcia-Ayllon
MS, Suarez I et al (2006) Brain oedema and inflammatory activation
in bile duct ligated rats with diet-induced hyperammonemia: a
model of hepatic encephalopathy in cirrhosis. Hepatology 43:
1257–1266
Kato M, Sugihara J, Nakamura T, Muto Y (1989) Electron microscopic
study of the blood–brain barrier (BBB) in rats with brain oedema
and encephalopathy due to acute hepatic failure. Gastroenterol Jpn
24:135–142
Kuhla A, Eipel C, Abshagen K, Siebert N, Menger MD, Vollmar B
(2009) Role of the perforin/granzyme cell death pathway in D-
Gal/LPS-induced inflammatory liver injury. Am J Physiol
Gastrointest Liver Physiol 296:G1069–1076
Langouche L, Vanhorebeek I, Vlasselaers D, Vander Perre S, Wouters PJ,
Skogstrand K, Hansen TK et al (2005) Intensive insulin therapy
protects the endothelium of critically ill patients. J Clin Invest 115:
2277–2286
Lee JC, Cho GS, Kim HJ, Lim JH, Oh YK, Nam W, Chung JH et al
(2005) Accelerated cerebral ischemic injury by activated
macrophages/microglia after lipopolysaccharide microinjection into
rat corpus callosum. Glia 50:168–181
Levesque E, Saliba F, Ichaï P, Samuel D (2013) Outcome at 1-year of
patients with cirrhosis admitted to ICU and requiring mechanical
ventilation. J Hepatol. doi:10.1016/j.jhep.2013.11.012
Liu XH, Chen Y, Wang TL, Lu J, Zhang LJ, Song CZ, Zhang J, Duan ZP
(2007) Establishment of a D-galactosamine/lipopolysaccharide in-
duced acute-on-chronic liver failure model in rats. Zhonghua
Ganzangbing Zazhi 15:771–775
Marcaida G, Felipo V, Hermenegildo C, Minana MD, Grisolia S (1992)
Acute ammonia toxicity is mediated by the NMDA type of gluta-
mate receptors. FEBS Lett 296:67–68
Murphy N, Auzinger G, Bernel W, Wendon J (2004) The effect of
hypertonic sodium chloride on intracranial pressure in patients with
acute liver failure. Hepatology 39:464–470
Nath K, Saraswat VA, Krishna YR, ThomasMA, Rathore RK, Pandey CM,
Gupta RK (2008) Quantification of cerebral edema on diffusion tensor
imaging in acute-on-chronic liver failure. NMR Biomed 21:713–722
Norenberg MD, Rao KV, Jayakumar AR (2005) Mechanisms of
ammonia-induced astrocyte swelling. Metab Brain Dis 20:303–318
972 Metab Brain Dis (2014) 29:965–973
Olson JC, Wendon JA, Kramer DJ, Vicente A, Jalan R, Garcia-Tsao G
et al (2011) Intensive care of the patient with cirrhosis. Hepatology
54:1864–1872
Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F,
Arroliga AC et al (2003) Correlation between ammonia levels and
the severity of hepatic encephalopathy. Am J Med 114:188–193
OriaM, Jalan R (2013) Brain lactate in hepatic encephalopathy: Friend or
foe? Journal of Hepatology (In press)]
Pedersen HR, Ring-Larsen H, Olsen NV, Larsen FS (2007)
Hyperammonemia acts synergistically with lipopolysaccharide in
inducing changes in cerebral hemodynamics in rats anaesthetised
with pentobarbital. J Hepatol 47:245–252
Peppiatt CM, Howarth C, Mobbs P, Attwell D (2006) Bidirectional
control of CNS capillary diameter by pericytes. Nature 443:700–704
Rao KV, Norenberg MD (2001) Cerebral energy metabolism in hepatic
encephalopathy and hyperammonemia. Metab Brain Dis 16:67–78
Rolando N, Harvey F, Brahm J, Philpott-Howard J, Alexander G, Gimson
A, Casewell M et al (1990) Prospective study of bacterial infection in
acute liver failure: an analysis of fifty patients. Hepatology 11:49–53
Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams
R (2000) The systemic inflammatory response syndrome in acute
liver failure. Hepatology 32:734–739
Rose C (2010) Increase brain lactate in hepatic encephalopathy: cause or
consequence? Neurochem Int 57:389–394
Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H et al
(2009) Acute-on chronic liver failure: consensus recommendations
of the Asian Pacific Association for the Study of the Liver (APASL).
Hepatol Int 3:269–282
Schliess F, Foster N, Gorg B, Reinehr R, Haussinger D (2004)
Hypoosmotic swelling increases protein tyrosine nitration in cul-
tured rat astrocytes. Glia 47:21–29
Sen S, Williams R, Jalan R (2002) The pathophysiological basis of acute-
on-chronic liver failure. Liver Int 22:5–13
Shawcross DL, Davies NA, Williams R, Jalan R (2004) Systemic
inflammatory response exacerbates the neuropsychological
effects of induced hyperammonemia in cirrhosis. J Hepatol
40:247–254
Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor
NJ (2011) Infection and systemic inflammation, not ammonia, are
associated with grade 3/4 hepatic encephalopathy, but not mortality
in cirrhosis. J Hepatol 54:640–649
Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M
(2006) Astrocyte-mediated control of cerebral blood flow. Nature
Neuroscience 9:260–267
Tofteng F, Hauerberg J, Hansen BA, Pedersen CB, Jorgensen L, Larsen
FS (2006) Persistent arterial hyperammonemia increases the con-
centration of glutamine and alanine in the brain and correlates with
intracranial pressure in patients with fulminant hepatic failure. J
Cereb Blood Flow Metab 26:21–27
Traber PG, Ganger DR, Blei AT (1986) Brain oedema in rabbits with
galactosamine-induced fulminant hepatitis. Regional differences and
effects on intracranial pressure. Gastroenterology 91:1347–1356
Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, Lee
WM et al (2003) Infection and the progression of hepatic encepha-
lopathy in acute liver failure. Gastroenterology 125:755–764
Verma A, Saraswat VA, Radha Krishna Y, Nath K, Thomas MA, Gupta
RK (2008) In vivo 1H magnetic resonance spectroscopy-derived
metabolite variations between acute-on-chronic liver failure and
acute liver failure. Liver Int 28:1095–1103
Wang LW, Wang LK, Chen H, Cheng F, Li X, He CM, Gong ZJ (2012)
Ethyl pyruvate protects against experimental acute-on-chronic liver
failure in rats. World J Gastroenterol 18:5709–5718
Wijdicks EF, Nyberg SL (2002) Propofol to control intracranial pressure
in fulminant hepatic failure. Transplant Proc 34:1220–1222
Wright G, Shawcross D, Jalan R (2007a) Brain cytokine flux in acute
liver failure and its relationship with intracranial hypertension.
Metab Brain Dis 22:375–388
Wright G, Davies NA, Shawcross DL, Hodges SJ, Harry D, Moore KP,
Mani A, Davies DC, Brooks HF, Williams R, Jalan R (2007b)
Endotoxaemia produces pre-coma and brain swelling in bile duct
ligated rats. Hepatology 45(6):1517–1526
Wright G, Newman TA, Sharifi Y, Davies NA, Perry H, Jalan R (2013)
Characterization of temporal microglia and astrocyte immune re-
sponses in bile-duct ligated rat models of cirrhosis (In press)
Metab Brain Dis (2014) 29:965–973 973
